The goal of this newsletter is to give an overview of what is happening around multiple myeloma in terms of medical developments. This is achieved by monitoring news articles, PR releases and scientific reports on one hand. Conversations from HCPs, digital opinion leaders and other influencers attending congresses, offering their opinion on treatments and commenting on new developments on the other hand.
Any professionals interested in keeping up with developments around multiple myeloma:
But also HCPs who want to anticipate the future landscape of MM management
The scope of the analysis is focused on mentions coming worldwide.*
There were a total of 49K mentions from patients recorded during the listening period from January 1st, 2023,to February 28th, 2023.
A majority of mentions came from News (43%), Twitter (39%), Instagram (12%), Forums (2%), Reddit (2%), Tumblr (1%)and blogs (1%).
A total of 12Kunique authors were identified.
*: Myeloma OR multiplemyeloma OR #Mmsm OR #Myeloma* OR #Curemyeloma* OR #Mmmrd OR #mmsm OR title: ("multiple myeloma" OR myeloma)
Some extracts from the multiple myeloma monthly newsletter
Hot off the press
FDA Grants Priority Review to Elranatamab in Relapsed/Refractory Myeloma
“The FDA has granted a priority review to the biologics license application for elranatamab for the treatment of patients with relapsed/refractory multiple myeloma.” Click here to read the full article
Media: volume and articles per peak
Volume of articles overtime
A“NHS spending watchdog approves three-drug treatment which lets blood cancer patients live longer - potentially helping 6,000 Britons with multiple myeloma a year“Link
“Inflammatory-Nutritional Score Helps Predict Survival in New Multiple Myeloma” Link
“Body Mass Index Tied to Multiple Myeloma Survival” Link
“Takeda’s Ninlaro (ixazomib) Receives NICE Recommendationfor the Treatment of Multiple Myeloma” Link
B“JanssenAnnounces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma”Link
C “Alternative To LenalidomideID’d For Maintenance In Multiple Myeloma” Link
D “Karyopharmand MenariniReceive Full Marketing Authorizationfrom the UK MHRA for NEXPOVIO(selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy” Link
E“Ide-Cel Beneficial in Relapsed, Refractory Multiple Myeloma” Link
F“Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma” Link
G “CASI PHARMACEUTICALSAND CLEAVE THERAPEUTICSANNOUNCE CLINICAL TRIAL APPLICATIONAPPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA” Link
“JanssenSubmits Marketing AuthorisationApplication to the European Medicines AgencySeeking Approval of Talquetamabfor the Treatment of Patients with Relapsed or Refractory Multiple Myeloma” Link
Drug Market Watch
January - February 2023
Fill this short form to discover the entire newsletter and to receive next SMML newsletters directly in your mailbox! 👇 👇